Cancer Patients Use THC and CBD Differently Than Other Medical Marijuana Patients

MedicalResearch.com Interview with:

Arum Kim, MDAssistant professor of Medicine and Rehabilitation MedicineNYU School of MedicineDirector of the Supportive Oncology ProgramPerlmutter Cancer Center

Dr. Kim

Arum Kim, MD
Assistant Professor
Medicine and Rehabilitation Medicine
NYU School of Medicine
Director of the Supportive Oncology Program
Perlmutter Cancer Center

MedicalResearch.com: What is the background for this study?  

Response: There is increasing interest in medical marijuana and its applications for patients with cancers. Despite increasing access, little is known regarding doses of cannabinoids – specifically tetrahydrocannabinol (THC)  and cannabidiol (CBD), methods of drug delivery, and differences in patterns of use between cancer and non-cancer patients.

Continue reading

Glaucoma: CBD (cannabidiol) May Raise Pressure in Eye

MedicalResearch.com Interview with:

Alex Straiker PhD Senior Scientist Psychological & Brain Sciences Indiana University 

Dr. Straiker

Alex Straiker PhD
Senior Scientist
Psychological & Brain Sciences
Indiana University 

MedicalResearch.com: What is the background for this study?

Response: We’ve known for almost 50 years that cannabis can lower ocular pressure but the mechanism of action was still unknown.  Most of the work on this stopped well before the cannabinoid receptors were discovered in the early 1990s.

Over the last several years we have determined that three different cannabinoid receptors (CB1, GPR18, and GPR119) each can lower pressure in mice when activated.  Once this was established, it made sense to go back to THC (and CBD) to see how they act.

MedicalResearch.com: What are the main findings? 

Response: There are four main findings.

  • Probably the most interesting is that CBD raises ocular pressure in mice.  Ours isn’t the first study to show this but we do show how it works.
  • Our second major finding is that THC lowers pressure through a combination of CB1 and GPR18 receptors.
  • The third major finding is that the effect of THC is sex-dependent, with longer effects in male mice.
  • Lastly, CBD cancels out the pressure-lowering effects of THC, probably by blocking CB1 receptors.  

MedicalResearch.com: What should readers take away from your report?

Response: There are two main take-homes.

  • There is a real possibility that CBD elevates ocular pressure and therefore the risk of glaucoma as a side-effect. This is significant given the widespread (and growing) availability of CBD and its recent FDA approval as a treatment for Dravet’s Syndrome.  Second, the sex-dependence is significant in and of itself but also because the current AAO position that topical THC is ineffective as a glaucoma therapy is based on four studies, three of which were small mixed-sex subject pools.  If the sex-dependence holds for humans, then it is possible that those studies yielded a false-negative result. 

MedicalResearch.com: What recommendations do you have for future research as a result of this work?

Response: The question of whether CBD raises ocular pressure in humans should be revisited and should be monitored in patients being treated for Dravet’s Syndrome.

No disclosures.   

Citation:

Sally Miller, Laura Daily, Emma Leishman, Heather Bradshaw, Alex Straiker. Δ9-Tetrahydrocannabinol and Cannabidiol Differentially Regulate Intraocular Pressure. Investigative Opthalmology & Visual Science, 2018; 59 (15): 5904 DOI: 10.1167/iovs.18-24838

 

[last-modified]

The information on MedicalResearch.com is provided for educational purposes only, and is in no way intended to diagnose, cure, or treat any medical or other condition. Always seek the advice of your physician or other qualified health and ask your doctor any questions you may have regarding a medical condition. In addition to all other limitations and disclaimers in this agreement, service provider and its third party providers disclaim any liability or loss in connection with the content provided on this website.

 

Katexco Pharmaceuticals To Develop Cannabis Derivative CBD to Suppress Inflammatory Conditions

Jonathan Rothbard, MA, PhD Steinman Lab Stanford Medicine Co-founder Katexco Pharmaceuticals

Dr. Rothbard

MedicalResearch.com Interview with:
Jonathan Rothbard, MA, PhD
Steinman Lab Stanford Medicine
Co-founder Katexco Pharmaceuticals

MedicalResearch.com: What is the background for this new company? How did Katexco get its name?

Response: Researchers with Stanford University, Jonathan Rothbard and Lawrence Steinman, formed Katexco Pharmaceuticals. Katexco will focus on developing oral therapies for inflammatory diseases based on cannabis and nicotine receptors.

Katexco will work to develop the first drug to focus on a key receptor on immune cells that are involved in inflammatory disease. The first primary target indications include gastrointestinal disorders like Crohn’s disease, gout and multiple sclerosis.

Katexco is from the Greek word to restrain or regulate, and we are trying to restrain the immune system in inflammatory disease.

Continue reading